PRTC PureTech Health

PureTech Health to Present at the Jefferies 2016 Healthcare Conference in London

PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biotech company developing 21st century medicines, today announced that Daphne Zohar, PureTech Health’s Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, at 4:00pm GMT.

A webcast of the presentation will be available at http://puretechhealth.com/investors.php under the Reports and Presentations tab.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech company creating 21st century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We are advancing more than 20 clinical studies across our pipeline, with five human proof-of-concept studies and multiple pivotal or registration studies expected to read out in the next two years. PureTech Health’s rich and growing research and development pipeline has been developed in collaboration with some of the world’s leading scientific experts, who along with PureTech's experienced team and board analyze more than 650 scientific discoveries per year to identify and advance the opportunities we believe hold the most promise for patients. This process places PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward- looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise.

EN
02/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PureTech Health

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc 08-Apr-2025 / 14:46 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(...

Puretech Health: 3 directors

Three Directors at Puretech Health sold 767,533 shares at 250p. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Liberum Research Team
  • Liberum Research Team

LIBERUM: Morning Comment

SAS Sentiment and Screens, Commodity snapSHOT, IAG, Endeavour Mining, Hargreaves Lansdown, Trainline, SIG, Cake Box, Aptamer, Market Highlights

Liberum Research Team
  • Liberum Research Team

LIBERUM: UK Small & Mid Cap Dispatches

SAS Sentiment and Screens, Commodity snapSHOT, Trainline, SIG, Cake Box, Aptamer, SMID Market Highlights

Liberum Research Team
  • Liberum Research Team

UK Small & Mid Cap Dispatches: Strategy - Equity market horse race, Al...

Strategy - Equity market horse race, Alts M&A up significantly in April, PureTech Health, Ferro-Alloy Resources, SMID Market Highlights

ResearchPool Subscriptions

Get the most out of your insights

Get in touch